Evidence map›Paper›PMID 37137904›Full record

ArticleBlood cancer journal2023

Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL.

Yan Qiu, Chao-Ling Wan, Ming-Zhu Xu, Hai-Xia Zhou, Mei-Jing Liu, Wen-Jie Gong, Li-Qing Kang, Ai-Ning Sun, Lei Yu, De-Pei Wu and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yan Qiu *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Chao-Ling Wan *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Ming-Zhu Xu *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Hai-Xia Zhou *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Mei-Jing LiuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Wen-Jie GongNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Li-Qing KangShanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, People's Republic of China.
Ai-Ning SunNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Lei YuShanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, People's Republic of China.
De-Pei WuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. drwudepei@163.com.ORCID 0000-0002-6312-3863
Chong-Sheng QianNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. qianchongsheng2006@163.com.ORCID 0000-0002-4237-1825
Sheng-Li XueNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. slxue@suda.edu.cn.ORCID 0000-0003-4609-616X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Burkitt LymphomaHematopoietic Stem Cell TransplantationReceptors, Chimeric AntigenAdultAntigens, CD19Consolidation ChemotherapyHumansImmunotherapy, AdoptiveSialic Acid Binding Ig-like Lectin 2Antigens, CD19CD22 protein, humanReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2

Identifiers

PMID37137904
PMCPMC10156719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.